title: Effectiveness of retinoic acid treatment for redifferentiation of thyroid cancer in relation to recovery of radioiodine uptake.
abstract: BACKGROUND
  Retinoic acid (RA) treatment has been used for redifferentiation of metastatic thyroid neoplasia that have lost radioiodine (131I) uptake with heterogeneous results.
  
  
  OBJECTIVE
  Retrospective analysis of the recovery rate of 131I uptake after RA treatment in patients from 11 Spanish hospitals.
  
  
  METHODS
  Twenty-seven patients (14 men, 13 women) with papillary [21], follicular [4], and oncocytic [2] thyroid cancer initially treated with total thyroidectomy plus 131I, and with 131I negative metastatic disease, were given 13-cis RA (0.66-1.5 mg/kg for 5-12 weeks) followed by a therapeutic 131I dose (3700-7400 MBq); 3 months later thyroglobulin levels and computed tomography imaging were performed.
  
  
  RESULTS
  In 9 out 27 cases (33%) (8 papillary, 1 follicular) optimal positive 131I scan was observed after RA treatment; in the remaining 18, 10 had a suboptimal uptake (7 papillary, 2 follicular, 1 oncocytic) and in the rest there was no 131I uptake recovery (6 papillary, 1 follicular, 1 oncocytic). In 17 positive responses to RA (either optimal or suboptimal) in which image follow-up was available, decrease or stabilization of metastatic growth was observed in 7, while tumor mass increased at short term in the remaining 10. No major side effects were detected.
  
  
  CONCLUSIONS
  Quite a high rate of 131I uptake recovery after RA treatment may be obtained in advanced differentiated thyroid cancer, but the potential modification of the natural course of the disease is uncertain. A better biological characterization of these tumors allowing the identification of potential responders to RA may improve the outcome of RA coadjuvant therapy.
authors: Endocrinology Service, Barcelona Clinical Hospital, Barcelona, Spain.
authors: C A
authors: CA
authors: Fernández
authors: M
authors: M
authors: Puig-Domingo
authors: F
authors: F
authors: Lomeña
authors: M
authors: M
authors: Estorch
authors: V
authors: V
authors: Camacho Martí
authors: A L
authors: AL
authors: Bittini
authors: M
authors: M
authors: Marazuela
authors: J
authors: J
authors: Santamaría
authors: J
authors: J
authors: Castro
authors: P
authors: P
authors: Martínez de Icaya
authors: I
authors: I
authors: Moraga
authors: T
authors: T
authors: Martín
authors: A
authors: A
authors: Megía
authors: M
authors: M
authors: Porta
authors: D
authors: D
authors: Mauricio
authors: I
authors: I
authors: Halperin
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000465:Algorithms; D018265:Carcinoma, Papillary, Follicular / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000534:rehabilitation; D002454:Cell Differentiation / Q000187:drug effects*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D015474:Isotretinoin / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011877:Radionuclide Imaging; D020127:Recovery of Function / Q000187:drug effects / Q000528:radiation effects; D012189:Retrospective Studies; D013964:Thyroid Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000534:rehabilitation; D016896:Treatment Outcome
chemical_list: D007457:Iodine Radioisotopes; D015474:Isotretinoin